Revised September 2023
Food and Drug Administration (FDA)
“8 Use in Specific Populations
8.1 Pregnancy: … Available data on COMIRNATY administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy…
8.2 Lactation: It is not known whether COMIRNATY is excreted in human milk. Data are not available to assess the effects of COMIRNATY on the breastfed infant or on milk production/excretion….
13 Nonclinical Toxicology
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility: COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility.”
document
adverse events,COVID-19,reproductive system issues,vaccines